A molecule can bind to its target with exquisite potency and still fail as a drug. The reason? ADMET—the pharmacokinetic and safety properties that determine whether a molecule can actually become a medicine.

Absorption: Can the drug get into the bloodstream? Distribution: Does it reach the right tissues? Metabolism: Is it broken down too quickly—or too slowly? Excretion: Can the body clear it safely? Toxicity: Does it cause unacceptable harm?

An estimated 40% of drug failures in clinical trials are attributed to poor pharmacokinetics or toxicity. These failures are particularly costly because they often occur in late-stage trials, after hundreds of millions of dollars have been invested.

The Traditional ADMET Challenge

Historically, ADMET properties were assessed through a combination of in vitro assays (cell-based experiments) and in vivo studies (animal testing). These experiments are time-consuming, expensive, and—in the case of animal studies—ethically fraught.

Worse, ADMET assessment was traditionally treated as a gatekeeping step rather than an integral part of the design process. Medicinal chemists would design a molecule for potency, then "throw it over the wall" to the ADMET team, only to learn weeks or months later that the compound had fatal pharmacokinetic liabilities.

This sequential approach is one of the primary reasons drug discovery takes so long.

AI-Driven ADMET Prediction

Machine learning models trained on large datasets of experimentally measured ADMET properties can now predict these parameters with remarkable accuracy. AgentCures' AI agent leverages these models to evaluate ADMET properties at the point of molecular design, not after synthesis.

This means:

  • Molecules with poor absorption are never synthesized. The AI agent evaluates oral bioavailability predictions before recommending any molecule for synthesis.
  • Metabolic liabilities are identified computationally. The agent predicts CYP450 interactions, metabolic soft spots, and clearance rates in silico.
  • Toxicity risks are flagged early. Structural alerts, hERG channel inhibition predictions, and reactive metabolite formation are assessed before a molecule ever enters a test tube.
  • Drug-drug interactions are anticipated. The agent evaluates potential interactions with commonly co-prescribed medications.

Multi-Property Optimization

The real power of AI in ADMET is not just prediction—it is optimization. AgentCures' generative molecular design engine optimizes for ADMET properties simultaneously with target potency and selectivity. This multi-property approach eliminates the traditional trade-off cycle where improving one property degrades another.

The AI agent navigates a chemical design space that balances:

  • Target binding affinity
  • Selectivity over related proteins
  • Oral bioavailability
  • Metabolic stability
  • Aqueous solubility
  • Permeability
  • Safety margins

Finding molecules that satisfy all of these constraints simultaneously is a needle-in-a-haystack problem for human chemists. For AI, it is a tractable optimization problem.

Reducing Animal Testing

AI-driven ADMET prediction has a significant ethical dimension. By accurately predicting pharmacokinetic and safety properties in silico, the need for animal testing can be substantially reduced. Molecules with obvious liabilities are eliminated computationally, meaning fewer compounds require animal studies.

AgentCures is committed to the principle that no animal experiment should be run if a computational approach can provide the same information. As our AI models improve, the proportion of questions that can be answered computationally will only increase.

The Impact on Development Timelines

By integrating ADMET prediction into the earliest stages of molecular design, AgentCures eliminates one of the most common sources of late-stage failure. Molecules that enter preclinical development from our pipeline have already been computationally vetted for drug-like properties, dramatically reducing the attrition rate as they progress through development.

The result is a faster, cheaper, and more predictable path from molecule to medicine. And for patients, it means safer drugs reaching the market sooner.